adpkd

MR-L2 is a reversible and noncompetitive allosteric activator of long-isoform phosphodiesterase-4 (PDE4).

H2-Gamendazole is a novel compound for spermatogenesis inhibition and cancer therapy as an inhibitor of heat shock proteins and or elongation factor 1 alpha, and is an Hsp90 regulator.

RGLS4326 (RG4326) is a short oligonucleotide inhibitor of microRNA-17 (miR-17), with a pioneering role in its class. This compound, with a research focus on autosomal dominant polycystic kidney disease (ADPKD), effectively suppresses the activity of miR-17 in HeLa cells, displaying an EC50 value of 28.3 nM.

Vasopressin V2 receptor antagonist 1 (Compound 4g) is a vasopressin V2receptor (V2R) antagonist (Ki: 3.8 nM). dominant polycystic kidney disease (ADPKD).

CDK7-IN-20 is a potent, selective, and irreversible inhibitor of Cyclin-Dependent Kinase 7 (CDK7) with an IC50 value of 4 nM, exhibiting over 206-fold selectivity against related kinases CDK1, CDK2, CDK3, CDK5, CDK6, CDK9, and CDK12. It holds potential for research into autosomal dominant polycystic kidney disease (ADPKD).

CDK5-IN-3 (compound 11) is a highly potent and selective inhibitor of CDK5, demonstrating significant inhibition with IC50 values of 0.6 nM and 18 nM for CDK5/p25 and CDK2/CycA, respectively. This compound holds promise for further investigation in the context of autosomal dominant polycystic kidney disease (ADPKD) research [1].